Annual Report 2012 - Acino

44
ACINO GROUP | FINANCIAL REPORT
5 Share capital/Treasury shares
On February 2, 2012, the capital was increased out of authorized capital totaling CHF 107 200 by 268 000, par value CHF 0.40 shares.
As of December 31, 2012, share capital amounted to CHF 1 384 million/EUR 0.9 million (as of December 31, 2011: CHF 1 277 million/
EUR 0.8 million) consisting of 3 460 000 (as of December 31, 2011: 3 192 000) registered, par value CHF 0.40 shares.
As of December 31, 2012, 22 133 treasury shares were held by Acino Holding AG. A portion of the treasury shares are intended for transfer
within the scope of the employee stock plan. There are no redemption obligations or contingent liabilities pertaining to the company’s shares.
6 Significant subsidiaries and affiliated companies
Consolidated subsidiaries:
Functional
currency
Par value of
capital
(in EUR 1 000)
Direct
equity
interest
Indirect
equity
interest
As of December 31, 2012
Switzerland
Acino Pharma AG, Liesberg EUR 2 323 100.0%
Acino supply AG, Aesch
Germany
EUR 65 100.0%
Acino AG, miesbach EUR 210 100.0%
mepha Pharma GmbH, Lörrach
France
EUR 52 100.0%
Acino France sAs, Alfortville
USA
EUR 10 100.0%
Acino Pharma Inc., Bridgewater (New Jersey)
Panama
EUR – 100.0%
Acino Latino-Americana s.A., Panama City EUR – 100.0%
Equity method on consolidated investments:
Functional
currency
Par value of
capital
(in EUR 1 000)
Direct
equity
interest
Indirect
equity
interest
As of December 31, 2012
India
Glochem Industries Ltd. INR 605 – 24.5%